OXOLIFE

📍 Barcelona, Spain🗓 Founded 2013👥 10 employees💰 Last funded Jul 2020
Biotechnology🌐 oxolife.com
Website LinkedIn
Oxolife : enhancing female fertility Oxolife is a small-size clinical-stage company focused on female fertility. We are currently developing an innovative treatment (OXO-001) to enhance female fertility success through acting on peri/post implantatory process. Additionally, OXO-001 restores ovulation. OXO-001 is a first in class drug due to its mechanism of action, solving an unmet need, since no solution drug in the embryo implantation market segment is available today. Is envisioned that the first phase II clinical trial will be completed by 2023. OXO-001 is protected by three different patents under the same umbrella which cover all the possible uses for female fertility. Oxolife’s team is leaded by Agnès Arbat, Medical Doctor (Co-founder and CEO) and Ignasi Canals, Biochemist PhD (Co-founder and CSO). Both accumulate a wide experience in the Women’s health pharmaceutical industry. The team has been supported by Clinical and Scientific Opinion Leaders from prestigious centers in fertility and R&D.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Spain
2
Frequently asked questions
Who invested in OXOLIFE?
OXOLIFE has 2 investors on record on gritt.io and 2 late-stage investors.
When did OXOLIFE last raise funding?
The most recent investment in OXOLIFE recorded on gritt.io was in July 2020.
When was OXOLIFE founded?
OXOLIFE was founded in 2013.
What industry is OXOLIFE in?
OXOLIFE operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is OXOLIFE based?
OXOLIFE is headquartered in Barcelona, Spain.